[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
1. Doi H, Ichikawa S, Hiraoka A, Ichiryu M, Nakahara H, Ochi H, Tanabe A, Kodama A, Hasebe A, Miyamoto Y, Ninomiya T, Horiike N, Takamura K, Kawasaki H, Kameoka C, Kan M, Doi S, Soga Y, Tamura H, Maeda T, Asaki A, Seno S, Iguchi H, Hasegawa T: Primitive neuroectodermal tumor of the pancreas. Intern Med; 2009;48(5):329-33
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primitive neuroectodermal tumor of the pancreas.
  • The primitive neuroectodermal tumor (PNET) of the pancreas, a member of Ewing's sarcoma family of tumors, is extremely rare.
  • We treated a 37-year-old Japanese man who had a solitary pancreatic tumor 40 mm in diameter and multiple hepatic tumors with surgical resection.
  • Fluorescence in situ hybridization (FISH) was also performed, which revealed a Ewing sarcoma breakpoint region 1 (EWSR1) 22q12 rearrangement.
  • According to the Japan-Ewing protocol, chemotherapy with Ifomide (ifosfamide), etoposide, vincristine, and cyclophosphamide was given after surgery.
  • Surgical resection was performed in most cases and some patients received postoperative chemotherapy.
  • [MeSH-major] Neuroectodermal Tumors, Primitive / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Calmodulin-Binding Proteins / genetics. Drug Therapy. Humans. Male. Positron-Emission Tomography. RNA-Binding Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19252356.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Calmodulin-Binding Proteins; 0 / EWSR1 protein, human; 0 / RNA-Binding Proteins
  •  go-up   go-down


2. Colovic RB, Grubor NM, Micev MT, Matic SV, Atkinson HD, Latincic SM: Perigastric extraskeletal Ewing's sarcoma: a case report. World J Gastroenterol; 2009 Jan 14;15(2):245-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perigastric extraskeletal Ewing's sarcoma: a case report.
  • Ewing's sarcoma (ES) is a neoplasm of undifferentiated small round cells, which occurs in the bones and deep soft tissues of children and adolescents.
  • Ultrasound and computed tomography scans indicated a solid/cystic mass in the pancreatic tail.
  • At laparotomy, the tumor was found attached to the posterior surface of the stomach, completely free from the pancreas, with no lymphadenopathy or local metastases.
  • The patient had no adjuvant chemotherapy; her postoperative recovery was uneventful, and she remains symptom-free, and without any sign of recurrence at 20 mo.
  • [MeSH-major] Sarcoma, Ewing / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, CD / metabolism. Cell Adhesion Molecules / metabolism. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Neuroectodermal Tumors, Primitive, Peripheral / immunology. Neuroectodermal Tumors, Primitive, Peripheral / pathology

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Spine (Phila Pa 1976). 2000 Aug 1;25(15):1996-9 [10908947.001]
  • [Cites] Jpn J Clin Oncol. 2005 Dec;35(12):753-6 [16332719.001]
  • [Cites] J R Coll Surg Edinb. 2001 Dec;46(6):372-4 [11768578.001]
  • [Cites] Hum Pathol. 2002 Jan;33(1):130-2 [11823984.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):320-7 [11859203.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Nov;23(8):530-2 [11878783.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):1040-7 [12170091.001]
  • [Cites] Tumori. 2002 Jul-Aug;88(4):345-6 [12400989.001]
  • [Cites] N Engl J Med. 2003 Feb 20;348(8):694-701 [12594313.001]
  • [Cites] Arch Pathol Lab Med. 2003 Apr;127(4):e190-3 [12683899.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Jun;12(2):160-5 [15354743.001]
  • [Cites] Skeletal Radiol. 1983;9(4):234-7 [6867772.001]
  • [Cites] Mod Pathol. 1994 Feb;7(2):200-4 [7911997.001]
  • [Cites] Can Assoc Radiol J. 1995 Apr;46(2):131-3 [7704678.001]
  • [Cites] Am J Pathol. 1996 Apr;148(4):1125-38 [8644855.001]
  • [Cites] Am J Surg Pathol. 1998 Nov;22(11):1417-22 [9808135.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 Nov;16(12):1391-400 [15618851.001]
  • [Cites] Arch Pathol Lab Med. 2005 Jan;129(1):107-10 [15628889.001]
  • [Cites] Obstet Gynecol. 2000 Nov;96(5 Pt 2):832-4 [11094227.001]
  • (PMID = 19132777.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules
  • [Other-IDs] NLM/ PMC2653319
  •  go-up   go-down


3. Mimeault M, Batra SK: Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers. Panminerva Med; 2008 Mar;50(1):3-18
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers.
  • The rapid progression from aggressive primary cancers into locally advanced and invasive and/or metastatic diseases remains a big obstacle for an early diagnosis and curative therapeutic intervention for cancer patients.
  • The late-stage leukemias and disseminated and metastatic sarcomas, melanomas, brain tumors and epithelial cancers are the devastating diseases associated with a high rate of recurrence after treatment with the conventional clinical therapies including surgery, ionizing radiation, hormonal therapy and systemic chemotherapy, which generally lead to the death of patients.
  • Therefore, the establishment of the molecular events underlying cancer initiation and progression into locally invasive and metastatic diseases is of major interest in basic cancer research as well as for the development of new effective clinical therapeutic options against the recurrent and lethal cancers.
  • Of therapeutic interest, the molecular targeting of deregulated signaling elements in cancer stem/progenitor cells and their local microenvironment represents a new potential strategy for the development of more effective clinical treatments against aggressive cancers.
  • Particularly, the combined use of chemotherapeutic drugs to eradicate cancer-initiating cells with hematopoietic stem cell or genetically-modified stem cell transplant is emerging as potential cancer treatments that hold great promise in the area of clinical cancer research.
  • These targeting and stem cell-based therapies may offer the ultimate hope for treating and even curing the patients diagnosed with locally advanced cancers at high risk of recurrence, metastatic and/or relapsed cancers in the clinics.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:82-101 [14633778.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1166-70 [14512297.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2332-6 [14630803.001]
  • [Cites] Cancer Lett. 2004 Feb 20;204(2):213-24 [15013220.001]
  • [Cites] Blood Rev. 2004 Sep;18(3):167-79 [15183901.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(10):1522-9 [15196536.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Jul;51(1):1-28 [15207251.001]
  • [Cites] Nat Immunol. 2004 Jul;5(7):738-43 [15170211.001]
  • [Cites] Transfusion. 2004 Jul;44(7):1087-97 [15225252.001]
  • [Cites] Panminerva Med. 2004 Mar;46(1):49-59 [15238881.001]
  • [Cites] Skin Pharmacol Physiol. 2004 Jul-Aug;17(4):153-66 [15258446.001]
  • [Cites] N Engl J Med. 2004 Aug 12;351(7):657-67 [15306667.001]
  • [Cites] N Engl J Med. 2004 Sep 2;351(10):998-1012 [15342808.001]
  • [Cites] Oncogene. 2004 Sep 20;23(43):7274-82 [15378087.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33 [15381773.001]
  • [Cites] Am J Pathol. 2006 Dec;169(6):2223-35 [17148683.001]
  • [Cites] Expert Opin Biol Ther. 2007 Jan;7(1):41-51 [17150018.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Neurobiol Dis. 2007 Feb;25(2):217-29 [17141509.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1113-20 [17283145.001]
  • [Cites] Stem Cells. 2007 Feb;25(2):371-9 [17038675.001]
  • [Cites] J BUON. 2006 Oct-Dec;11(4):433-8 [17309174.001]
  • [Cites] Nature. 2007 Feb 22;445(7130):851-7 [17314971.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2187-96 [17332349.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Mar;20(1):57-65 [17336255.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Feb;5(2):203-15 [17335689.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4635-40 [17299092.001]
  • [Cites] Genes Dev. 2007 Jun 1;21(11):1382-95 [17510286.001]
  • [Cites] Pediatr Blood Cancer. 2007 Aug;49(2):196-8 [17417796.001]
  • [Cites] Mol Vis. 2007;13:823-32 [17615543.001]
  • [Cites] Carcinogenesis. 2007 Jul;28(7):1379-86 [17341655.001]
  • [Cites] Clin Exp Metastasis. 2007;24(5):353-62 [17487557.001]
  • [Cites] Clin Pharmacol Ther. 2007 Sep;82(3):252-64 [17671448.001]
  • [Cites] Stem Cells Dev. 2007 Aug;16(4):637-48 [17784837.001]
  • [Cites] Stem Cells. 2007 Sep;25(9):2302-11 [17569791.001]
  • [Cites] Ann Oncol. 2007 Oct;18(10):1605-19 [17355951.001]
  • [Cites] Carcinogenesis. 2007 Sep;28(9):2053-8 [17434930.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2125-31 [17565741.001]
  • [Cites] Clin Exp Metastasis. 2007;24(7):485-93 [17653825.001]
  • [Cites] Pigment Cell Res. 2007 Dec;20(6):458-65 [17935489.001]
  • [Cites] Cancer Treat Rev. 2008 May;34(3):247-58 [18226859.001]
  • [Cites] Stem Cell Rev. 2008 Spring;4(1):27-49 [18288619.001]
  • [Cites] Blood. 2000 Feb 1;95(3):1007-13 [10648416.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1166-73 [11493466.001]
  • [Cites] Lancet Oncol. 2002 Jan;3(1):35-43 [11905603.001]
  • [Cites] Nat Immunol. 2002 Jul;3(7):687-94 [12068293.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):175-8 [12242149.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5657-63 [12384520.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):826-35 [12415253.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7170-4 [12499252.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Pathol Oncol Res. 2003;9(1):13-9 [12704441.001]
  • [Cites] Growth Factors. 2003 Mar;21(1):1-14 [12795332.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):685-94 [12951587.001]
  • [Cites] Cell Mol Life Sci. 2005 Aug;62(16):1863-70 [16003493.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):744-9 [16148886.001]
  • [Cites] Mini Rev Med Chem. 2005 Sep;5(9):805-24 [16178723.001]
  • [Cites] Ernst Schering Found Symp Proc. 2006;(5):155-79 [17939301.001]
  • [Cites] Oncologist. 2007 Oct;12(10):1237-46 [17962617.001]
  • [Cites] Front Biosci. 2008;13:1887-91 [17981676.001]
  • [Cites] J Cell Mol Med. 2007 Sep-Oct;11(5):981-1011 [17979879.001]
  • [Cites] Med Princ Pract. 2008;17(1):84-5 [18059108.001]
  • [Cites] Br J Hosp Med (Lond). 2007 Nov;68(11):589-93 [18087845.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2008 Feb;49(2):636-43 [18235009.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):626-32 [18235122.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Feb;5(2):102-11 [18235442.001]
  • [Cites] Nat Rev Cancer. 2006 Jun;6(6):425-36 [16723989.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1299-308 [16731763.001]
  • [Cites] Eur J Cancer. 2006 Jun;42(9):1309-15 [16682183.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6063-71 [16778178.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2891-6 [16782928.001]
  • [Cites] J Cell Biochem. 2006 Jul 1;98(4):757-69 [16598744.001]
  • [Cites] Hepatology. 2006 Jul;44(1):240-51 [16799977.001]
  • [Cites] Curr Drug Targets. 2006 Jul;7(7):861-79 [16842217.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 [16849428.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7445-52 [16885340.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1533-8 [16871285.001]
  • [Cites] Cell Cycle. 2006 Aug;5(15):1597-601 [16880743.001]
  • [Cites] Pediatr Blood Cancer. 2006 Oct 15;47(5):560-6 [16395684.001]
  • [Cites] Leuk Lymphoma. 2006 Aug;47(8):1545-52 [16966265.001]
  • [Cites] Mol Cancer Res. 2006 Sep;4(9):607-19 [16966431.001]
  • [Cites] Bone Marrow Transplant. 2006 Oct;38(7):493-9 [16980997.001]
  • [Cites] Hum Mol Genet. 2006 Oct 15;15 Spec No 2:R210-9 [16987886.001]
  • [Cites] Ann Oncol. 2006 Nov;17(11):1620-4 [16600978.001]
  • [Cites] Stem Cells. 2006 Nov;24(11):2319-45 [16794264.001]
  • [Cites] Klin Padiatr. 2006 Nov-Dec;218(6):321-6 [17080334.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):160-9 [17013895.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16870-5 [17077147.001]
  • [Cites] Panminerva Med. 2006 Sep;48(3):165-74 [17122752.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:219-25 [17124064.001]
  • [Cites] J Cell Mol Med. 2006 Oct-Dec;10(4):857-65 [17125590.001]
  • [Cites] J Cell Mol Med. 2006 Oct-Dec;10(4):995-1013 [17125601.001]
  • [Cites] Clin Invest Med. 2006 Oct;29(5):301-11 [17144440.001]
  • [Cites] Exp Cell Res. 2006 Nov 15;312(19):3701-10 [17046749.001]
  • [Cites] Mol Vis. 2005;11:729-37 [16179903.001]
  • [Cites] Hematology. 2005 Oct;10(5):349-59 [16203604.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Oct;5(5):835-46 [16221053.001]
  • [Cites] Expert Rev Vaccines. 2005 Oct;4(5):699-710 [16221071.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):323-35 [16226707.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9328-37 [16230395.001]
  • [Cites] Chest. 2005 Oct;128(4):2268-73 [16236883.001]
  • [Cites] Pancreas. 2005 Nov;31(4):301-16 [16258363.001]
  • [Cites] Curr Opin Neurol. 2005 Dec;18(6):639-44 [16280674.001]
  • [Cites] Cancer Lett. 2005 Dec 18;230(2):199-210 [16297706.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2304-12 [16193083.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Haematologica. 2007 Mar;92(3):323-31 [17339181.001]
  • [Cites] PLoS One. 2007;2(3):e293 [17356702.001]
  • [Cites] Br J Haematol. 2007 Apr;137(1):20-35 [17359369.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):967-78 [17363490.001]
  • [Cites] Semin Cancer Biol. 2007 Jun;17(3):241-7 [16839774.001]
  • [Cites] Bone Marrow Transplant. 2007 Apr;39(7):397-400 [17322933.001]
  • [Cites] Cancer Metastasis Rev. 2007 Mar;26(1):203-14 [17273942.001]
  • [Cites] J Thorac Oncol. 2007 Apr;2(4):327-43 [17409807.001]
  • [Cites] Adv Cancer Res. 2007;97:25-60 [17419940.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2007 Mar;115(3):160-5 [17427103.001]
  • [Cites] Oncology. 2006;71(1-2):32-9 [17344669.001]
  • [Cites] Exp Gerontol. 2007 May;42(5):385-90 [17275237.001]
  • [Cites] Curr Eye Res. 2007 Mar;32(3):281-90 [17453948.001]
  • [Cites] Leukemia. 2007 May;21(5):926-35 [17330101.001]
  • [Cites] Nat Rev Drug Discov. 2006 Aug;5(8):649-59 [16883303.001]
  • [Cites] Leukemia. 2007 May;21(5):949-55 [17361218.001]
  • [Cites] Cancer Cell. 2007 May;11(5):421-9 [17482132.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jun;62(3):214-26 [17368038.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2007 Jun 29;362(1482):959-71 [17317642.001]
  • [Cites] Trends Mol Med. 2007 May;13(5):192-9 [17383232.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jun 15;357(4):1084-9 [17466949.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4807-15 [17510410.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4827-33 [17510412.001]
  • [Cites] J Cell Sci. 2007 Feb 1;120(Pt 3):468-77 [17227796.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] Nature. 1984 Feb 2-8;307(5950):471-3 [6694739.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):165-72 [9440739.001]
  • [Cites] Nat Med. 1998 Sep;4(9):1038-45 [9734397.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):324-31 [15549094.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Springer Semin Immunopathol. 2004 Nov;26(1-2):95-108 [15378271.001]
  • [Cites] Oncogene. 2004 Dec 16;23(58):9392-400 [15558011.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):293-300 [15637392.001]
  • [Cites] Carcinogenesis. 2005 Feb;26(2):495-502 [15513931.001]
  • [Cites] Cell Cycle. 2004 Dec;3(12):1502-5 [15611623.001]
  • [Cites] Nat Rev Cancer. 2005 Feb;5(2):91-101 [15685194.001]
  • [Cites] J Neurooncol. 2005 Jan;71(1):33-8 [15719272.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):275-84 [15803154.001]
  • [Cites] Bone Marrow Transplant. 2005 Apr;35(8):763-6 [15750608.001]
  • [Cites] Med Hypotheses. 2005;64(6):1182-7 [15823713.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3025-9 [15833827.001]
  • [Cites] Am J Clin Oncol. 2005 Jun;28(3):281-8 [15923802.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4490-5 [15930263.001]
  • [Cites] Breast Cancer Res. 2005;7(3):86-95 [15987436.001]
  • [Cites] J Pediatr Surg. 2005 Jun;40(6):936-41; discussion 941 [15991174.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5506-11 [15994920.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6207-19 [16024622.001]
  • [Cites] Neoplasia. 2005 Jun;7(6):623-9 [16036113.001]
  • [Cites] Lancet. 2005 Jul 23-29;366(9482):318-20 [16039336.001]
  • [Cites] Br J Haematol. 2005 Aug;130(3):373-81 [16042686.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):119-30 [16098465.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):811-22 [16120861.001]
  • [Cites] Cancer Cell. 2008 Feb;13(2):153-66 [18242515.001]
  • [Cites] Cell Death Differ. 2008 Mar;15(3):504-14 [18049477.001]
  • [Cites] J Cell Physiol. 2008 May;215(2):287-91 [18205182.001]
  • [Cites] BMC Cancer. 2008;8:48 [18261235.001]
  • [Cites] Growth Factors. 2007 Dec;25(6):400-16 [18365871.001]
  • [Cites] Cell Stem Cell. 2007 Sep 13;1(3):313-23 [18371365.001]
  • [Cites] Endocr Rev. 2008 Apr;29(2):234-52 [18292464.001]
  • [Cites] Clin Pharmacol Ther. 2008 May;83(5):673-91 [17786164.001]
  • [Cites] Breast Cancer Res. 2008;10(1):R10 [18241344.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 9):S78-81 [16399438.001]
  • [Cites] J Invest Dermatol. 2006 Jan;126(1):142-53 [16417230.001]
  • [Cites] J Exp Med. 2006 Jan 23;203(1):73-85 [16380511.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):1022-31 [16108016.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):859-66 [16419074.001]
  • [Cites] Nat Rev Drug Discov. 2006 Feb;5(2):147-59 [16424916.001]
  • [Cites] Cell Cycle. 2006 Feb;5(4):452-6 [16479164.001]
  • [Cites] Oncogene. 2006 Mar 16;25(12):1696-708 [16449977.001]
  • [Cites] J Pediatr Surg. 2006 Apr;41(4):624-32; discussion 624-32 [16567167.001]
  • [Cites] Stem Cells. 2006 Mar;24(3):506-13 [16239320.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1924-31 [16567768.001]
  • [Cites] Hum Cell. 2006 Feb;19(1):24-9 [16643604.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4553-7 [16651403.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4532-9 [16469872.001]
  • [Cites] Leuk Lymphoma. 2006 Jan;47(1):1-7 [16321820.001]
  • [Cites] Neoplasia. 2005 Nov;7(11):967-76 [16331882.001]
  • [Cites] Nature. 2005 Dec 8;438(7069):820-7 [16341007.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11459-68 [16357154.001]
  • [Cites] Carcinogenesis. 2006 Jan;27(1):1-22 [16195239.001]
  • [Cites] Nat Rev Neurosci. 2006 Jan;7(1):75-84 [16371952.001]
  • [Cites] Adv Cancer Res. 2007;96:23-50 [17161675.001]
  • [Cites] Mol Cancer. 2006;5:67 [17140455.001]
  • [Cites] Mod Pathol. 2007 Jan;20(1):102-7 [17143262.001]
  • [Cites] Semin Diagn Pathol. 2006 May;23(2):63-9 [17193819.001]
  • [Cites] PLoS Med. 2006 Dec;3(12):e482 [17194186.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] PLoS One. 2006;1:e23 [17183650.001]
  • [Cites] Pediatr Blood Cancer. 2007 Mar;48(3):349-53 [16302216.001]
  • [Cites] Annu Rev Med. 2007;58:267-84 [17002552.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Expert Opin Biol Ther. 2006 Dec;6(12):1255-62 [17223735.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8 [17210912.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Curr Biol. 2007 Jan 23;17(2):165-72 [17196391.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Feb;13(2):235-44 [17241929.001]
  • [Cites] Neurosurg Clin N Am. 2007 Jan;18(1):59-69, viii-ix [17244554.001]
  • [Cites] Neurosurg Clin N Am. 2007 Jan;18(1):71-80, ix [17244555.001]
  • (PMID = 18427384.001).
  • [ISSN] 0031-0808
  • [Journal-full-title] Panminerva medica
  • [ISO-abbreviation] Panminerva Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA078590; United States / NCI NIH HHS / CA / U01 CA111294; United States / NCI NIH HHS / CA / CA111294; United States / NCI NIH HHS / CA / CA78590
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] Italy
  • [Number-of-references] 210
  • [Other-IDs] NLM/ NIHMS526856; NLM/ PMC3828640
  •  go-up   go-down


Advertisement
4. Kanno S, Tomizawa A, Hiura T, Osanai Y, Shouji A, Ujibe M, Ohtake T, Kimura K, Ishikawa M: Inhibitory effects of naringenin on tumor growth in human cancer cell lines and sarcoma S-180-implanted mice. Biol Pharm Bull; 2005 Mar;28(3):527-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitory effects of naringenin on tumor growth in human cancer cell lines and sarcoma S-180-implanted mice.
  • We have investigated the effect of naringenin (NGEN) on tumor growth in various human cancer cell lines and sarcoma S-180-implanted mice.
  • NGEN showed cytotoxicity in cell lines derived from cancer of the breast (MCF-7, MDA-MB-231), stomach (KATOIII, MKN-7), liver (HepG2, Hep3B, Huh7), cervix (Hela, Hela-TG), pancreas (PK-1), and colon (Caco-2) as well as leukemia (HL-60, NALM-6, Jurkat, U937).
  • In vivo, NGEN inhibited tumor growth in sarcoma S-180-implanted mice, following intraperitoneal or peroral injection once a day for 5 d.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Flavanones / therapeutic use. Growth Inhibitors / pharmacology. Sarcoma 180 / drug therapy
  • [MeSH-minor] Animals. Cell Line, Tumor. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor / methods. Humans. Male. Mice

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15744083.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Flavanones; 0 / Growth Inhibitors; HN5425SBF2 / naringenin
  •  go-up   go-down


5. Jancík S, Drábek J, Radzioch D, Hajdúch M: Clinical relevance of KRAS in human cancers. J Biomed Biotechnol; 2010;2010:150960
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The KRAS gene (Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) is an oncogene that encodes a small GTPase transductor protein called KRAS.
  • Activating mutations in the KRAS gene impair the ability of the KRAS protein to switch between active and inactive states, leading to cell transformation and increased resistance to chemotherapy and biological therapies targeting epidermal growth factor receptors.
  • It also underlines the importance of activating mutations in the KRAS gene in relation to carcinogenesis and their importance as diagnostic biomarkers, providing clues regarding human cancer patients' prognosis and indicating potential therapeutic approaches.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochemistry. 1998 Sep 29;37(39):13453-62 [9753431.001]
  • [Cites] Carcinogenesis. 1999 Aug;20(8):1507-10 [10426799.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Dec;54(6):497-504 [15258697.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Jan;20(1):67-72 [15610449.001]
  • [Cites] Cell. 2005 Jan 14;120(1):15-20 [15652477.001]
  • [Cites] Nature. 2005 Feb 17;433(7027):769-73 [15685193.001]
  • [Cites] J Cell Sci. 2005 Mar 1;118(Pt 5):843-6 [15731001.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Ann Oncol. 2005 May;16 Suppl 4:iv50-55 [15923430.001]
  • [Cites] Expert Opin Pharmacother. 2005 Jun;6(6):985-93 [15952926.001]
  • [Cites] J Mol Diagn. 2005 Aug;7(3):413-21 [16049314.001]
  • [Cites] J Cell Biol. 2005 Aug 1;170(3):429-41 [16043511.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5900-9 [16043828.001]
  • [Cites] Oncogene. 2005 Sep 1;24(38):5878-87 [15897875.001]
  • [Cites] Electrophoresis. 2005 Sep;26(17):3380-6 [16097023.001]
  • [Cites] Oncologist. 2005 Sep;10(8):565-78 [16177281.001]
  • [Cites] Biochim Biophys Acta. 2005 Nov 25;1756(2):81-2 [16269215.001]
  • [Cites] Methods. 2005 Oct;37(2):165-72 [16288888.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1647-53 [16533793.001]
  • [Cites] Br J Cancer. 2006 Mar 27;94(6):896-903 [16552419.001]
  • [Cites] Nucleic Acids Res. 2006;34(9):2536-49 [16687659.001]
  • [Cites] Cancer Biol Ther. 2006 Oct;5(10):1392-9 [17106238.001]
  • [Cites] Cancer Biol Ther. 2006 Nov;5(11):1481-6 [17172815.001]
  • [Cites] Mol Cancer Res. 2007 Feb;5(2):195-201 [17314276.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):295-308 [17384584.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):2890-6 [17504988.001]
  • [Cites] J Epidemiol Community Health. 2007 Jul;61(7):641-9 [17568059.001]
  • [Cites] Biochim Biophys Acta. 2007 Aug;1773(8):1177-95 [17428555.001]
  • [Cites] Curr Treat Options Oncol. 2007 Feb;8(1):28-37 [17634830.001]
  • [Cites] J Int Med Res. 2007 Jul-Aug;35(4):450-7 [17697521.001]
  • [Cites] Mol Interv. 2007 Aug;7(4):199-202, 180 [17827440.001]
  • [Cites] Nucleic Acids Res. 2007;35(19):e131 [17932053.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):374-9 [18202412.001]
  • [Cites] Hum Mutat. 2008 Mar;29(3):441-50 [18186519.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1296-302 [18316547.001]
  • [Cites] Exp Mol Pathol. 2008 Apr;84(2):79-89 [18279851.001]
  • [Cites] Med J Aust. 2008 Sep 1;189(5):277-82 [18759727.001]
  • [Cites] J Mol Diagn. 2008 Nov;10(6):520-6 [18832461.001]
  • [Cites] Strahlenther Onkol. 2008 Nov;184(11):592-7 [19016018.001]
  • [Cites] Leukemia. 2008 Dec;22(12):2269-72 [18509354.001]
  • [Cites] J Thorac Oncol. 2009 Jan;4(1):12-21 [19096301.001]
  • [Cites] Gastroenterology. 2009 Feb;136(2):459-70 [19026650.001]
  • [Cites] Biochem Soc Trans. 2009 Apr;37(Pt 2):427-32 [19290875.001]
  • [Cites] Biochem Soc Trans. 2009 Apr;37(Pt 2):433-7 [19290876.001]
  • [Cites] Am Rev Respir Dis. 1990 Dec;142(6 Pt 2):S27-30 [2252272.001]
  • [Cites] Trends Genet. 1991 Mar;7(3):91-5 [2031288.001]
  • [Cites] Mol Cell Biol. 1992 May;12(5):2050-6 [1569940.001]
  • [Cites] Genes Chromosomes Cancer. 1992 Sep;5(2):109-18 [1381946.001]
  • [Cites] Environ Health Perspect. 1992 Nov;98:13-24 [1486840.001]
  • [Cites] Electrophoresis. 2006 May;27(10):1878-85 [16619298.001]
  • [Cites] Am J Hum Genet. 2006 Jul;79(1):129-35 [16773572.001]
  • [Cites] Clin Chem. 2006 Oct;52(10):1855-63 [16916990.001]
  • [Cites] Semin Oncol. 2006 Oct;33(5 Suppl 10):S26-34 [17145522.001]
  • [Cites] Biochem J. 2003 Dec 15;376(Pt 3):e9-10 [14656216.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):437-50 [14706336.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004 [14973191.001]
  • [Cites] Electrophoresis. 2004 Apr;25(7-8):1016-21 [15095442.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):545-54 [8342602.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1626-34 [18316791.001]
  • [Cites] Pharmacotherapy. 2008 Jun;28(6):742-54 [18503402.001]
  • [Cites] Curr Med Chem. 2008;15(15):1478-92 [18537624.001]
  • [Cites] Biochem Pharmacol. 2008 Jul 15;76(2):198-207 [18561895.001]
  • [Cites] Cancer Metastasis Rev. 2008 Sep;27(3):403-14 [18461427.001]
  • [Cites] Br J Cancer. 2009 Mar 24;100(6):985-92 [19293811.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):432-8 [8319174.001]
  • [Cites] Clin Chem Lab Med. 1999 Sep;37(9):877-81 [10596953.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):144-52 [10655059.001]
  • [Cites] J Epidemiol Community Health. 1999 Nov;53(11):702-9 [10656099.001]
  • [Cites] Int J Oncol. 2000 Mar;16(3):501-11 [10675482.001]
  • [Cites] Nature. 2000 Feb 24;403(6772):901-6 [10706289.001]
  • [Cites] Nucleic Acids Res. 2000 Oct 1;28(19):3752-61 [11000267.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1193-7 [11097226.001]
  • [Cites] Clin Chem. 2000 Dec;46(12):1929-38 [11106325.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):488-99 [11505392.001]
  • [Cites] Nat Genet. 2001 Sep;29(1):25-33 [11528387.001]
  • [Cites] Science. 2001 Oct 26;294(5543):853-8 [11679670.001]
  • [Cites] Mutat Res. 2002 Jan 15;513(1-2):37-48 [11719088.001]
  • [Cites] Semin Oncol. 2001 Oct;28(5 Suppl 17):19-26 [11740803.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1525-30 [11745231.001]
  • [Cites] Nat Genet. 2002 Apr;30(4):363-4 [11896390.001]
  • [Cites] Cancer. 2002 Apr 1;94(7):2055-62 [11932909.001]
  • [Cites] J Virol. 2002 May;76(9):4275-86 [11932393.001]
  • [Cites] Acta Biochim Pol. 2001;48(4):829-50 [11995995.001]
  • [Cites] Anal Biochem. 2002 May 15;304(2):200-5 [12009696.001]
  • [Cites] Oncogene. 2002 Jun 20;21(27):4301-6 [12082617.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):4142-50 [12124353.001]
  • [Cites] Mol Biotechnol. 2002 Oct;22(2):115-21 [12405259.001]
  • [Cites] Mol Cancer Ther. 2001 Nov;1(1):29-41 [12467236.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(2):543-54 [12509453.001]
  • [Cites] Oncogene. 2003 Feb 27;22(8):1243-6 [12606951.001]
  • [Cites] Cell. 2003 Apr 4;113(1):25-36 [12679032.001]
  • [Cites] J Am Chem Soc. 2003 Jun 11;125(23):6937-45 [12783546.001]
  • [Cites] J Biol Chem. 2003 Aug 22;278(34):31871-8 [12805379.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):111-20 [12957286.001]
  • [Cites] Mol Cancer Res. 2003 Oct;1(12):882-91 [14573789.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3753-6 [15172979.001]
  • [Cites] Br J Cancer. 2004 Jul 19;91(2):355-8 [15188009.001]
  • [Cites] Clin Chem. 2004 Sep;50(9):1688-91 [15331511.001]
  • [Cites] Lung Cancer. 2004 Nov;46(2):255-61 [15474674.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Aug;79(16):4848-52 [6289320.001]
  • [Cites] Cell. 1983 Jan;32(1):201-8 [6825168.001]
  • [Cites] Nature. 1983 Mar 3;302(5903):79-81 [6298638.001]
  • [Cites] Nature. 1983 Aug 11-17;304(5926):501-6 [6308466.001]
  • [Cites] Mol Cell Biol. 1983 Dec;3(12):2298-301 [6197628.001]
  • [Cites] Nucleic Acids Res. 1983 Dec 10;11(23):8221-36 [6672765.001]
  • [Cites] Somat Cell Mol Genet. 1985 Mar;11(2):149-55 [3856955.001]
  • [Cites] Nature. 1987 May 28-Jun 3;327(6120):293-7 [3587348.001]
  • [Cites] Nature. 1987 May 28-Jun 3;327(6120):298-303 [2438556.001]
  • [Cites] Annu Rev Biochem. 1987;56:779-827 [3304147.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Nucleic Acids Res. 1989 Apr 11;17(7):2503-16 [2785681.001]
  • [Cites] Cell. 1989 Jun 30;57(7):1167-77 [2661017.001]
  • [Cites] Eur J Clin Invest. 1990 Jun;20(3):225-35 [2114981.001]
  • [Cites] Cell. 1993 Dec 3;75(5):843-54 [8252621.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6257-64 [7954475.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1171-3 [7577015.001]
  • [Cites] Semin Oncol. 1995 Dec;22(6 Suppl 14):12-8 [8553077.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3368-74 [8605354.001]
  • [Cites] Int J Cancer. 1997 Mar 17;70(6):661-7 [9096646.001]
  • [Cites] Gut. 1997 May;40(5):660-3 [9203947.001]
  • [Cites] Pancreas. 1997 Jul;15(1):16-24 [9211488.001]
  • [Cites] Science. 1997 Jul 18;277(5324):333-8 [9219684.001]
  • [Cites] J Biol Chem. 1997 Oct 3;272(40):25128-34 [9312123.001]
  • [Cites] J Biol Chem. 1997 Oct 31;272(44):27902-7 [9346938.001]
  • [Cites] J Biol Chem. 1997 Nov 28;272(48):30362-70 [9374526.001]
  • [Cites] Exp Cell Res. 1997 Nov 25;237(1):7-13 [9417860.001]
  • [Cites] J Pathol. 1998 Jun;185(2):130-8 [9713338.001]
  • (PMID = 20617134.001).
  • [ISSN] 1110-7251
  • [Journal-full-title] Journal of biomedicine & biotechnology
  • [ISO-abbreviation] J. Biomed. Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ PMC2896632
  •  go-up   go-down


6. Tsukahara T, Nabeta Y, Kawaguchi S, Ikeda H, Sato Y, Shimozawa K, Ida K, Asanuma H, Hirohashi Y, Torigoe T, Hiraga H, Nagoya S, Wada T, Yamashita T, Sato N: Identification of human autologous cytotoxic T-lymphocyte-defined osteosarcoma gene that encodes a transcriptional regulator, papillomavirus binding factor. Cancer Res; 2004 Aug 1;64(15):5442-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The prognosis for patients with osteosarcoma who do not respond to current chemotherapy protocols still remains poor.
  • Toward the goal of establishing efficacious peptide-based immunotherapy for those patients, we previously developed an autologous pair of CTLs and an osteosarcoma cell line.
  • Reverse transcription-PCR analysis revealed that PBF was expressed in 16 of 19 cases of bone and soft-tissue sarcoma cell lines (5 of 6 of osteosarcoma lines) and 57 of 76 sarcoma tissue samples (11 of 14 of osteosarcoma tissues).
  • Also, PBF was expressed in 10 of 13 epithelial cancer cell lines and 20 of 34 of cancer tissues.
  • In contrast, PBF was detected in some normal organs including ovary, pancreas, spleen, and liver by reverse transcription-PCR but was restricted in the cytoplasm by immunostaining and undetectable by Western blotting.

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15289353.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / HLA-A Antigens; 0 / Peptide Fragments
  •  go-up   go-down


7. Tsai TC, Rosing JH, Norton JA: Role of factor VII in correcting dilutional coagulopathy and reducing re-operations for bleeding following non-traumatic major gastrointestinal and abdominal surgery. J Gastrointest Surg; 2010 Aug;14(8):1311-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Seventeen patients with postoperative hemorrhage following major abdominal gastrointestinal surgery (nine pancreas, four sarcoma, two gastric, one carcinoid, and one fistula) were treated with rfVIIa.
  • [MeSH-major] Blood Coagulation Disorders / drug therapy. Digestive System Surgical Procedures / adverse effects. Factor VII / therapeutic use. Gastrointestinal Diseases / surgery. Hemostasis / physiology. Postoperative Hemorrhage / drug therapy. Reoperation / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Bleeding Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood Coagul Fibrinolysis. 2000 Apr;11 Suppl 1:S129-32 [10850578.001]
  • [Cites] Arch Surg. 1984 Apr;119(4):369-74 [6703892.001]
  • [Cites] Ann Thorac Surg. 2008 May;85(5):1669-76; discussion 1676-7 [18442563.001]
  • [Cites] Anesth Analg. 2010 Feb 1;110(2):354-64 [20007735.001]
  • [Cites] World J Gastroenterol. 2010 Jan 7;16(1):98-103 [20039455.001]
  • [Cites] J Am Coll Surg. 2009 Aug;209(2):198-205 [19632596.001]
  • [Cites] Am J Surg. 2009 May;197(5):565-70; discussion 570 [19393349.001]
  • [Cites] J Intensive Care Med. 2009 Mar-Apr;24(2):116-21 [19188273.001]
  • [Cites] J Cardiothorac Vasc Anesth. 2009 Feb;23(1):34-40 [19081268.001]
  • [Cites] Am Surg. 2008 Dec;74(12):1159-65 [19097529.001]
  • [Cites] Arch Surg. 2008 Oct;143(10):1001-7; discussion 1007 [18936380.001]
  • [Cites] Ann Surg. 2008 Sep;248(3):447-58 [18791365.001]
  • [Cites] Crit Care. 2008;12(1):R14 [18279513.001]
  • [Cites] Arch Surg. 2008 Mar;143(3):296-304; discussion 304 [18347278.001]
  • [Cites] J Trauma. 2008 Feb;64(2):286-93; discussion 293-4 [18301188.001]
  • [Cites] Ann Surg. 2007 Aug;246(2):269-80 [17667506.001]
  • [Cites] N Engl J Med. 2007 May 31;356(22):2301-11 [17538089.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(2):CD005011 [17443565.001]
  • [Cites] Crit Care. 2006;10(6):R178 [17184516.001]
  • [Cites] Dig Surg. 2006;23(4):203-8 [16873999.001]
  • [Cites] N Engl J Med. 2006 Sep 28;355(13):1303-5 [17005947.001]
  • [Cites] Crit Care. 2006;10(4):R120 [16919168.001]
  • [Cites] Am Surg. 2005 Sep;71(9):776-80 [16468517.001]
  • [Cites] Intern Med J. 2005 Aug;35(8):463-7 [16176468.001]
  • [Cites] J Trauma. 2005 Jul;59(1):8-15; discussion 15-8 [16096533.001]
  • [Cites] Crit Care Med. 2005 Apr;33(4):883-90 [15818119.001]
  • [Cites] Blood Coagul Fibrinolysis. 1998 Mar;9 Suppl 1:S61-5 [9819030.001]
  • [Cites] Ann Surg. 1998 Feb;227(2):236-41 [9488522.001]
  • [Cites] Arch Surg. 1997 Jun;132(6):620-4; discussion 624-5 [9197854.001]
  • [Cites] Pancreas. 2003 Jan;26(1):101-2 [12499928.001]
  • [Cites] Lancet. 2003 Jan 18;361(9353):201-5 [12547542.001]
  • [Cites] Transfusion. 2003 Dec;43(12):1711-6 [14641868.001]
  • [Cites] Vox Sang. 2004 Feb;86(2):120-4 [15023181.001]
  • [Cites] Crit Care Med. 2002 Oct;30(10):2249-54 [12394952.001]
  • (PMID = 20517651.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 9001-25-6 / Factor VII
  • [Other-IDs] NLM/ PMC2909430
  •  go-up   go-down


8. Breccia M, D'Andrea M, Mengarelli A, Morano SG, D'Elia GM, Alimena G: Granulocytic sarcoma of the pancreas successfully treated with intensive chemotherapy and stem cell transplantation. Eur J Haematol; 2003 Mar;70(3):190-2
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma of the pancreas successfully treated with intensive chemotherapy and stem cell transplantation.
  • A case of preleukemic granulocytic sarcoma of pancreas is presented.
  • Pancreas is a well described site of secondary metastasis of solid tumors, but occasionally it has been reported as the primary site of leukemia.
  • We highlight the importance of an accurate immunohistochemical diagnosis and of an early and intensive acute myeloid leukemia-like treatment for these cases representing an uncommon and aggressive form of acute leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hematopoietic Stem Cell Transplantation. Pancreatic Neoplasms / therapy. Sarcoma, Myeloid / therapy
  • [MeSH-minor] Adult. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Lymphoma / diagnosis. Remission Induction / methods

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12605665.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


9. Dimicoli S, Feugier P, Delaby P, Cannard L, Bland V, Witz F, Hulin C, Guerci A, Labouyrie E, Lederlin P: [Granulocyte sarcoma of the pancreas without extra-pancreatic location]. Presse Med; 2002 Jun 22;31(22):1024-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Granulocyte sarcoma of the pancreas without extra-pancreatic location].
  • [Transliterated title] Sarcome granulocytaire du pancréas sans autre localisation extra-pancréatique.
  • INTRODUCTION: Granulocyte sarcoma (GS), also known as chloroma, is a localized malignant tumor composed of myeloid cells, the diagnosis of which is difficult.
  • The pancreatic location and recurrence, aside from any context of malignant hemopathy, are exceptional.
  • OBSERVATION: A 31-year-old woman developed an isolated and recurrent granulocyte sarcoma of the pancreas, without any context of a malignant hemopathy.
  • The diagnosis retained on extemporaneous examination was an adenocarcinoma of the pancreas, because of the non-specific necrotic nature of the tumor.
  • The immuno-histochemical exploration corrected the diagnosis.
  • This relapse was treated with radiotherapy followed by heavy chemotherapy, identical to that applied in acute myeloblastic leukemia (AML).
  • COMMENTS: Isolated granulocyte sarcomas located in the pancreas are exceptional and have often led to initial erroneous diagnosis.
  • Immuno-histochemical methods are essential in order to obtain correct diagnosis.
  • Despite the localized nature of the tumor, intensive AML-type chemotherapy is necessary.
  • [MeSH-major] Adenocarcinoma / pathology. Neoplasm Recurrence, Local. Pancreatic Neoplasms / pathology. Sarcoma, Myeloid / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12148256.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


10. Di Matteo FM, De Stefano M, Vanni B, Palermo S, Biancafarina A, Giusti D, Savino G, Di Marco C, Casalvieri L, De Antoni E: [Retroperitoneal giant mixed sarcoma. Case report]. G Chir; 2008 May;29(5):238-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Retroperitoneal giant mixed sarcoma. Case report].
  • [Transliterated title] Un caso di sarcoma misto retroperitoneale gigante.
  • CT scan showed a solid abdominal expansive mass, with compression and displacement of the left lobe of the liver, spleen, stomach, pancreas, and left kidney.
  • The prognosis of these tumours is closely related to local recurrence, histological type, size and radical surgery.
  • Radiation therapy and chemotherapy do not seem to have a strong influence on the prognosis.
  • An aggressive surgical approach is the first choice for the treatment of such tumors.
  • [MeSH-minor] Adult. Female. Humans. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18507961.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


11. Morooka M, Ito K, Kubota K, Minamimoto R, Shida Y, Hasuo K, Ito T, Tasato D, Honda H, Teruya K, Kikuchi Y, Ohtomo K: Whole-body 18F-fluorodeoxyglucose positron emission tomography/computed tomography images before and after chemotherapy for Kaposi sarcoma and highly active antiretrovirus therapy. Jpn J Radiol; 2010 Dec;28(10):759-62
MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole-body 18F-fluorodeoxyglucose positron emission tomography/computed tomography images before and after chemotherapy for Kaposi sarcoma and highly active antiretrovirus therapy.
  • Kaposi sarcoma is an acquired immunodeficiency syndrome-related disease that mainly involves the skin, gastrointestinal gut, and lungs.
  • Whole-body 18F-fluorodeoxyglucose-positron emission tomography and computed tomography (FDG-PET/CT) scanning is useful for simultaneous detection of multiple lesions of Kaposi sarcoma.
  • After Kaposi sarcoma therapy, the uptake in the lesions of the skin, lung, and lymph nodes decreased, but new lesions were detected in the pancreas and lumbar spine.
  • After therapy, FDG-PET/CT can be used to demonstrate which lesions remain active and to determine the overall response to treatment.
  • In this case, we show how useful FDG-PET/CT is and how difficult it is to treat Kaposi sarcoma.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods. Sarcoma, Kaposi / diagnosis. Tomography, X-Ray Computed / methods. Whole Body Imaging / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2007 Mar 15;109(6):1040-52 [17265518.001]
  • [Cites] Clin Nucl Med. 2008 Sep;33(9):624-6 [18716513.001]
  • [Cites] J Nucl Med. 1992 Nov;33(11):1972-80 [1432158.001]
  • [Cites] Radiographics. 2006 Jul-Aug;26(4):1169-85 [16844940.001]
  • [Cites] JAMA. 2003 Mar 5;289(9):1106 [12622579.001]
  • [Cites] Curr HIV Res. 2009 Nov;7(6):634-8 [19929800.001]
  • [Cites] J Nucl Med. 1996 Oct;37(10 ):1662-7 [8862304.001]
  • [Cites] J Clin Pathol. 2005 Jun;58(6):626-8 [15917415.001]
  • (PMID = 21191742.001).
  • [ISSN] 1867-108X
  • [Journal-full-title] Japanese journal of radiology
  • [ISO-abbreviation] Jpn J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


12. Yin WH, Yu GY, Ma Y, Rao HL, Lin SX, Shao CK, Liang Q, Guo N, Chen GQ, Zhou W, Zhao T, Zhu MG: [Follicular dendritic cell sarcoma: a clinicopathologic analysis of ten cases]. Zhonghua Bing Li Xue Za Zhi; 2010 Aug;39(8):522-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Follicular dendritic cell sarcoma: a clinicopathologic analysis of ten cases].
  • OBJECTIVE: To study the clinicopathologic features of follicular dendritic cell sarcoma (FDCS) and its differential diagnosis.
  • Six of them were located in cervical and peritoneal lymph nodes and four in extranodal sites (including tonsil, pelvic cavity, tail of pancreas and spleen).
  • The remaining 5 patients were alive and disease-free after surgical excision (+/- chemotherapy and radiotherapy).
  • Appropriate application of FDC markers, such as CD21, CD35 and D2-40, would be helpful for arriving at a correct diagnosis.
  • Most cases are associated with good prognosis after surgical treatment, with or without chemotherapy and radiotherapy.
  • [MeSH-major] Dendritic Cell Sarcoma, Follicular / pathology. Lymph Nodes / pathology. Tonsillar Neoplasms / pathology
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived / metabolism. Dendritic Cell Sarcoma, Interdigitating / pathology. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Lymph Node Excision. Male. Meningioma / pathology. Middle Aged. Nasopharyngeal Neoplasms / pathology. Paraneoplastic Syndromes / complications. Pemphigus / complications. Receptors, Complement 3b / metabolism. Receptors, Complement 3d / metabolism. Receptors, IgE / metabolism. Young Adult

  • Genetic Alliance. consumer health - TEN.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21055030.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Receptors, Complement 3b; 0 / Receptors, Complement 3d; 0 / Receptors, IgE; 0 / monoclonal antibody D2-40
  •  go-up   go-down


13. Yang GC, Wang J, Yee HT: Interwoven dendritic processes of follicular dendritic cell sarcoma demonstrated on ultrafast papanicolaou-stained smears: a case report. Acta Cytol; 2006 Sep-Oct;50(5):534-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interwoven dendritic processes of follicular dendritic cell sarcoma demonstrated on ultrafast papanicolaou-stained smears: a case report.
  • CASE: We observed novel cytologic features of FDC sarcoma in a liver fine needle aspirate of a 46-year-old man status post surgery and chemotherapy for FDC sarcoma, originating in the gastrointestinal tract with metastases to the liver, pancreas and spleen.
  • CONCLUSION: The ultrastructural features of a web of interwoven, dendritic, cytoplasmic processes of FDC tumor was demonstrated for the first time on cytology.
  • Observation of this feature may allow the diagnosis to be made on cytology prior to histology, immunohistochemistry or electron microscopy.
  • [MeSH-major] Dendritic Cells, Follicular / pathology. Gastrointestinal Neoplasms / pathology. Liver Neoplasms / diagnosis. Sarcoma / diagnosis
  • [MeSH-minor] Antigens, Surface / analysis. Antigens, Surface / immunology. Antigens, Surface / metabolism. Biomarkers, Tumor / analysis. Biomarkers, Tumor / immunology. Biomarkers, Tumor / metabolism. Biopsy, Needle. Cell Shape. Diagnosis, Differential. Humans. Liver / pathology. Lymph Nodes / pathology. Male. Middle Aged. Papanicolaou Test / methods. Papanicolaou Test / standards. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17017440.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / Biomarkers, Tumor
  •  go-up   go-down


14. Cseh A, Szebeni B, Szalay B, Vásárhelyi B: [Akt enzyme: new therapeutic target in cancer and diabetes?]. Orv Hetil; 2009 Feb 22;150(8):373-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Akt enzyme: new therapeutic target in cancer and diabetes?].
  • Proteins responsible for the regulation of apoptosis are therapeutic targets; these include the Akt enzyme.
  • Akt enzyme is expressed in most cell types.
  • Akt activation is regulated by growth factors, insulin, and also environmental factors as altered oxygen tension and high temperature.
  • An increased activity of Akt has been described in prostate, breast, colon, and pancreatic cancer, as well as in hematological malignancies.
  • Several studies revealed that some of the marketed drugs including statins, thiazolidinediones and ACE inhibitors modulate Akt activity.
  • There are efforts to develop specific Akt inhibitors that may improve the efficacy of chemotherapy.
  • Triciribine and perifosine are two Akt inhibitors in developmental phase 1 and 2 that may improve survival in breast cancer, pancreas cancer, gastrointestinal stroma tumor, sarcoma and melanoma, and in hematological malignancy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Diabetes Mellitus / drug therapy. Diabetes Mellitus / enzymology. Hypoglycemic Agents / therapeutic use. Neoplasms / drug therapy. Neoplasms / enzymology. Proto-Oncogene Proteins c-akt / metabolism
  • [MeSH-minor] Apoptosis. Cell Movement. Cell Proliferation. Enzyme Activation / drug effects. Humans. Insulin Resistance. Neovascularization, Pathologic. Neovascularization, Physiologic. Phosphorylcholine / analogs & derivatives. Phosphorylcholine / therapeutic use. Ribonucleosides / therapeutic use

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19218147.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hypoglycemic Agents; 0 / Ribonucleosides; 107-73-3 / Phosphorylcholine; 2421HMY9N6 / triciribine; 2GWV496552 / perifosine; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


15. Chiappori A, Simon GR, Kvols L, Tetteh L, Mahany JJ, Lush R, Sullivan DM: Phase I trial of carboplatin, irinotecan and etoposide in advanced solid tumors. J Clin Oncol; 2004 Jul 15;22(14_suppl):2132

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carboplatin(C), Irinotecan(T) and Etoposide (E) are drugs with a broad spectrum of activity.
  • RESULTS: A total of 10 patients were enrolled from April 2002 to October 2002.Patient characteristics were M/F 5/5; age range 24 to 65, ECOG PS 0/1=1/9; number of prior treatments 0/1/2/3= 4/2/3/1; median number of cycles given=3 (range 1 - 8).
  • Tumor types enrolled were NSCLC = 3, Carcinoid = 3, and 1 each of Head and Neck Cancer, Mesothelioma, Sarcoma and Islet Cell Cancer of the pancreas.
  • The subsequent cohort of 6 patients tolerated chemotherapy well with no first-cycle or second-cycle grade III or IV neutropenia or thrombocytopenia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016906.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Syed SK, Beeram M, Takimoto CH, Jakubowitz J, Kimura M, Ducharme M, Gadgeel S, De Jager R, Rowinsky E, Lorusso P: Phase I and Pharmacokinetics (PK) of DJ-927, an oral taxane, in patients (Pts) with advanced cancers. J Clin Oncol; 2004 Jul 15;22(14_suppl):2028

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pts were stratified based on prior therapy into minimally (MP) and heavily (HP) pretreated cohorts.
  • Primary tumors are colorectal [15], breast [4], pancreas [5], renal cell [3], soft tissue sarcoma [3] and others [10].
  • Minimal drug-related toxicities were observed at doses 5 days duration [7] and grade 3 thrombocytopenia [4] were the predominant hematological toxicities observed at 40 and 35 mg/m<sup>2</sup> doses.
  • CONCLUSIONS: DJ-927 generates predictable systemic drug exposures and has been well tolerated when orally administered.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015577.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Ratain MJ, Flaherty KT, Stadler WM, O'Dwyer P, Kaye S, Xiong H, Patnaik A, Gore M, Lee RJ, Eisen T: Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). J Clin Oncol; 2004 Jul 15;22(14_suppl):4501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common tumor types were colorectal (CRC), renal cell carcinoma (RCC) and melanoma.
  • Typical drug-related toxicities were hand-foot skin reaction, rash, fatigue, diarrhea, anorexia and hypertension.
  • Tumor regressions were observed in multiple tumor types including RCC, CRC, melanoma, thyroid, sarcoma and pancreas.
  • CONCLUSIONS: BAY has activity (as measured by disease regressions) in multiple tumor types, particularly RCC, and is well tolerated in pts with advanced cancers.
  • An ongoing phase III study in RCC will assess BAY's effect on time to progression and survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016014.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Eilber FC, Eilber KS, Eilber FR: Retroperitoneal sarcomas. Curr Treat Options Oncol; 2000 Aug;1(3):274-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Imaging of the abdomen and pelvis by computed tomography (CT) provides both an imaging modality and a method by which to obtain tissue for diagnosis.
  • Because a histologic diagnosis is essential in treatment planning, adequate tissue can usually be obtained by a CT-guided core biopsy.
  • If the diagnosis is sarcoma, additional tests necessary for staging include plain chest radiography and evaluation of the liver by either CT scan or magnetic resonance imaging (MRI).
  • The treatment options for primary retroperitoneal sarcomas include chemotherapy, radiation therapy, surgery, or a combination of these modalities; therefore, a multidisciplinary group best manages treatment planning.
  • Primary radiation therapy for cure is seldom effective for retroperitoneal sarcomas but can provide palliation in select cases.
  • Systemic chemotherapy for chemosensitive lesions, such as poorly differentiated liposarcoma, malignant fibrous histiocytoma (MFH), synovial cell sarcoma, and primitive neuroectodermal tumors (PNET), can be useful when used in a neoadjuvant manner.
  • Consequently, surgical resection continues to be the mainstay of treatment for retroperitoneal sarcomas and requires en bloc resection of the primary tumor.
  • Frequently this includes adjacent organs such as colon, small bowel, kidney, adrenal, and pancreas.
  • Postoperative adjuvant therapy with chemotherapy or radiation has not been proven to be of any additional benefit.
  • Overall treatment results are predominantly influenced by tumor stage, grade, size, and margins of surgical resection.
  • [MeSH-major] Retroperitoneal Neoplasms / therapy. Sarcoma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biopsy / methods. Clinical Trials as Topic. Combined Modality Therapy. Humans. Neoplasm Recurrence, Local / pathology. Radiotherapy. Survival Rate

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 1996 Apr;182(4):329-39 [8605556.001]
  • [Cites] Surg Oncol. 1998 Jul-Aug;7(1-2):77-81 [10421510.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1600-8 [7541449.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1077-83 [10091791.001]
  • [Cites] Arch Surg. 1991 Mar;126(3):328-34 [1998475.001]
  • [Cites] J Clin Oncol. 1990 Jan;8(1):170-8 [2104923.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):355-65 [9742918.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2832-9 [9256126.001]
  • [Cites] Cancer. 1977 May;39(5):1940-8 [858124.001]
  • [Cites] Ann Intern Med. 1982 Feb;96(2):133-9 [7059060.001]
  • [Cites] Cancer. 1994 May 15;73(10):2506-11 [8174046.001]
  • [Cites] Ann Surg. 1991 Jul;214(1):2-10 [2064467.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):185-95 [7857146.001]
  • [Cites] Adv Surg. 1997;31:395-420 [9408503.001]
  • [Cites] Br J Surg. 1991 Aug;78(8):912-6 [1913104.001]
  • [Cites] Oncology (Williston Park). 1996 Dec;10(12):1867-72; discussion 1872-4 [8985970.001]
  • [Cites] Arch Surg. 1993 Apr;128(4):402-10 [8457152.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):1005-10 [8083069.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5):526-33 [9344318.001]
  • (PMID = 12057171.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 21
  •  go-up   go-down


19. Kato Y: [WT1 peptide pulsed dendritic cell therapy with activated T lymphocytes therapy for advanced cancers]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2240-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [WT1 peptide pulsed dendritic cell therapy with activated T lymphocytes therapy for advanced cancers].
  • We assessed the efficacy of WT1 peptide pulsed dendritic cell (DC) therapy for various advanced cancers.
  • All patients were vaccinated 5 times for 10 weeks with autologous monocytes derived DC and activated T lymphocytes.
  • We evaluated 20 of the 26 patients who finished 5-time vaccination (10 men and 10 women, aged 48-81 years, Mean 64 years) and were diagnosed as follows: 3-pancreas cancer, 2-colorectal, 2-breast, 2-esophageal, 2-lung, 2-uterus, 2-ovarian and 5 others.
  • Furthermore, the 7 PRs were resulted from 2-colorectal, and one of each was lung, laryngeal, axis, pancreas and smooth muscle sarcoma cancer.
  • The 4 of 7 PR patients were treated with chemotherapy.
  • [MeSH-major] Cancer Vaccines / administration & dosage. Lymphocyte Activation. Neoplasms / therapy. T-Lymphocyte Subsets / immunology. WT1 Proteins / immunology
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Dendritic Cells / immunology. Female. Humans. Immunotherapy, Active / methods. Male. Middle Aged. Picibanil / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224534.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cancer Vaccines; 0 / WT1 Proteins; 39325-01-4 / Picibanil
  •  go-up   go-down


20. Berber E, Ari E, Herceg N, Siperstein A: Laparoscopic radiofrequency thermal ablation for unusual hepatic tumors: operative indications and outcomes. Surg Endosc; 2005 Dec;19(12):1613-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: There is increasing experience with laparoscopic radiofrequency ablation for the treatment of patients with hepatic metastasis from colorectal and neuroendocrine cancer and those with hepatocellular cancer.
  • Little is known about the outcomes for patients with other tumor types.
  • Among these, 53 patients (10%) had cancers other than the colorectal, neuroendocrine, or hepatocellular types including sarcoma (n = 18), breast cancer (n = 10), esophagus cancer (n = 4), melanoma (n = 4), lung cancer (n = 3), ovarian cancer (n = 2), pancreas cancer (n = 2), unknown primary cancer (n = 2), cholangiocarcinoma (n = 2), rectal squamous cancer (n = 2), renal cancer (n = 2), papillary thyroid cancer (n = 1), and hemangioendothelioma (n = 1).
  • Unlike the criteria for treatment of the more usual tumor types, these patients had a diagnosis of liver-exclusive disease, as diagnosed by preoperative imaging.
  • They also had failed chemotherapy.
  • RESULTS: The 53 patients underwent ablation of 192 lesions, with 8 patients undergoing repeat treatment.
  • The overall median survival was 33 months for the whole series, more than 51 months for breast cancer, and 25 months for sarcoma.
  • CONCLUSION: Laparoscopic radiofrequency ablation can safely and effectively treat hepatic metastasis of these unusual tumor types.
  • The authors believe that this heterogeneous group of patients, selected for their unusual presentation of liver-exclusive disease, may benefit from cytoreduction of their tumor by laparoscopic radiofrequency ablation when other treatment methods have failed.
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Endosc. 2000 Apr;14(4):400-5 [10790563.001]
  • [Cites] World J Surg. 2002 Aug;26(8):985-90 [12016479.001]
  • [Cites] Surg Endosc. 2005 May;19(5):710-4 [15759186.001]
  • [Cites] Am J Surg. 2003 Feb;185(2):158-64 [12559448.001]
  • [Cites] Hepatogastroenterology. 1998 Jan-Feb;45(19):201-5 [9496513.001]
  • [Cites] Am Surg. 1999 Nov;65(11):1009-14 [10551746.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):72-5 [7740813.001]
  • [Cites] J Gastrointest Surg. 1998 Mar-Apr;2(2):151-5 [9834411.001]
  • [Cites] Surgery. 1997 Jun;121(6):625-32 [9186462.001]
  • [Cites] Arch Surg. 2001 Aug;136(8):950-5 [11485537.001]
  • [Cites] Ann Surg Oncol. 2001 May;8(4):379-80 [11352313.001]
  • [Cites] Cancer. 1995 Oct 1;76(7):1120-5 [8630886.001]
  • [Cites] Ann Surg Oncol. 2000 Mar;7(2):106-13 [10761788.001]
  • [Cites] Ann Surg. 1999 Jul;230(1):1-8 [10400029.001]
  • [Cites] Oncologist. 2003;8(3):241-51 [12773746.001]
  • [Cites] Surgery. 1997 Dec;122(6):1147-54; discussion 1154-5 [9426432.001]
  • [Cites] Ann Surg. 1995 Apr;221(4):392-7 [7726675.001]
  • [Cites] Ann Surg. 2001 Oct;234(4):540-7; discussion 547-8 [11573047.001]
  • [Cites] Arch Surg. 2001 Aug;136(8):864-9 [11485520.001]
  • [Cites] J Vasc Interv Radiol. 1999 Jul-Aug;10(7):907-16 [10435709.001]
  • [Cites] J Surg Res. 1999 Nov;87(1):114-21 [10527712.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1358-64 [15684312.001]
  • [Cites] Ann Thorac Surg. 2003 Jul;76(1):291-3 [12842567.001]
  • (PMID = 16247574.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


21. Dillman RO, Soori G, DePriest C, Nayak SK, Beutel LD, Schiltz PM, de Leon C, O'Connor AA: Treatment of human solid malignancies with autologous activated lymphocytes and cimetidine: a phase II trial of the cancer biotherapy research group. Cancer Biother Radiopharm; 2003 Oct;18(5):727-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of human solid malignancies with autologous activated lymphocytes and cimetidine: a phase II trial of the cancer biotherapy research group.
  • OBJECTIVE: The Cancer Biotherapy Research Group conducted a clinical trial to verify encouraging reports of antitumor activity of autolymphocyte therapy.
  • PATIENTS AND METHODS: Patients with a variety of advanced solid malignancies underwent an initial leukapheresis procedure to collect about 5 x 10(9) autologous lymphocytes that were stimulated in vitro for 3 days with anti-CD3 monoclonal antibody in the presence of indomethicin and cis-retinoic acid to obtain media that was frozen in aliquots.
  • These were administered intravenously monthly for up to 6 months with daily oral cimetidine at a dose of 600 mg po qid, which was given throughout the treatment period.
  • One hundred seventy four treatments were delivered and were well tolerated.
  • Objective tumor responses were observed in 1/15 renal cell, 1/13 colorectal, 0/6 breast, 0/5 lung, 0/2 gastric, 0/2 sarcoma, 0/1 pancreas, 0/1 prostate, 0/1 melanoma, and 0/1 eccrine.
  • CONCLUSION: This complex treatment program was feasible.
  • [MeSH-major] Adoptive Transfer. Cell- and Tissue-Based Therapy. Cimetidine / therapeutic use. Lymphocytes / immunology. Neoplasms / drug therapy. Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIMETIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14629821.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 80061L1WGD / Cimetidine
  •  go-up   go-down


22. Nakamoto Y, Saga T, Ishimori T, Higashi T, Mamede M, Okazaki K, Imamura M, Sakahara H, Konishi J: FDG-PET of autoimmune-related pancreatitis: preliminary results. Eur J Nucl Med; 2000 Dec;27(12):1835-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this retrospective study was to elucidate the fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) findings in autoimmune-related pancreatitis (AIP), which is a reversible chronic pancreatitis with an autoimmune cause.
  • In four of the six patients, PET demonstrated intense uptake in the whole pancreas, which appeared swollen on computed tomography, and the accumulation increased with time in three patients.
  • In one patient, intense focal uptake in the pancreatic head was observed, and the accumulation decreased over time.
  • In the remaining patient, no abnormal accumulation in the pancreas was observed.
  • Follow-up PET scanning after steroid therapy was performed in three patients, and intense FDG uptake was no longer observed.
  • Our preliminary data show that AIP can cause intense FDG uptake in the pancreas.
  • This fact, and the benign status of the condition, should be kept in mind when making a diagnosis with FDG-PET in patients with pancreatic disorders.
  • [MeSH-major] Furans / pharmacokinetics. Organophosphorus Compounds / pharmacokinetics. Organotechnetium Compounds / pharmacokinetics. Radiopharmaceuticals / pharmacokinetics. Sarcoma / metabolism. Technetium Tc 99m Sestamibi / pharmacokinetics
  • [MeSH-minor] Cell Survival / drug effects. Chondrosarcoma / metabolism. Fibrosarcoma / metabolism. Humans. Liposarcoma / metabolism. Sarcoma, Synovial / metabolism. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11189947.001).
  • [ISSN] 0340-6997
  • [Journal-full-title] European journal of nuclear medicine
  • [ISO-abbreviation] Eur J Nucl Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Furans; 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane; 0 / technetium Tc 99m Q12; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


23. Cautero N, De Luca S, Vecchi A, Garelli P, Nicolini D, Martorelli G, Frascà GM, Gaffi G, Taruscia D, Bearzi I, Adani G, Risaliti A: Peritoneal leiomyosarcoma in a kidney transplant patient: a case report. Transplant Proc; 2007 Jul-Aug;39(6):2038-9
Hazardous Substances Data Bank. SIROLIMUS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our present report focused on a 46-year-old woman who received immunosuppressive therapy based on cyclosporine and steroids for renal transplantation.
  • Eight years after transplantations, she suffered lower abdominal pain and a mass involving peritoneal soft tissues was located near the right iliac vessels.
  • After 30 days, a computed tomography scan revealed two small pulmonary metastases, so the patient received adriamycin.
  • Six months after the diagnosis, there was no intra-abdominal relapse and the pulmonary metastasis remain stable.
  • Sarcomas in solid organ transplant patients appear to have aggressive features with 62% being high grade and 40% metastatic at the time of primary diagnosis with a recurrence rate of 30% and a 5-year survival rate of 25%.
  • Patients diagnosed with sarcoma should be treated with multimodality therapy.
  • After aggressive surgery whenever possible, a combination of a traditional cytotoxic drug and a "signal" blocking agent like rapamycin may increase selectivity toward tumor cells.
  • [MeSH-major] Kidney Transplantation. Leiomyosarcoma / diagnosis. Peritoneal Neoplasms / diagnosis. Sirolimus / therapeutic use
  • [MeSH-minor] Female. Humans. Immunosuppressive Agents / therapeutic use. Lung Neoplasms / pathology. Middle Aged. Neoplasm Metastasis. Postoperative Complications / diagnosis. Postoperative Complications / radiography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17692686.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


24. André T, Wislez M, Goncalves A, de La Motte Rouge T, Blay JY, Massard C, Bay JO, comité de rédaction du Bulletin du Cancer: [Following communications made at American Society of Clinical Oncology 2010, what will change our practice? The point of view of the editorial board of Bulletin du Cancer]. Bull Cancer; 2010 Dec;97(12):1551-62

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Suite aux communications faites au congrès de l'American Society of Clinical Oncology 2010, qu'est ce qui va changer nos pratiques ? Le point de vue du comité de rédaction du Bulletin du cancer.
  • Best understanding of biological mechanisms and new molecules to inhibit targets allow in certain case, to use therapeutic targeting in the true sense.
  • In Advanced non-small cell lung cancer, myeloma and advanced lymphoma, maintenance therapy by monoclonal anti-body or inhibitors of tyrosines kinases showed the proof of their effectiveness.
  • In metastatic adenocarcinoma of the pancreas, there is finally an alternative to gemcitabine with the Folfirinox regimen, with an improvement of overall survival.
  • Biological personalization of cancer treatments is on the road run but the road is still long.
  • [MeSH-major] Medical Oncology / standards. Neoplasms / therapy. Practice Patterns, Physicians' / standards. Societies, Medical / standards
  • [MeSH-minor] Breast Neoplasms / therapy. Digestive System Neoplasms / therapy. Female. Gastrointestinal Stromal Tumors / drug therapy. Genital Neoplasms, Female / drug therapy. Hematologic Neoplasms / therapy. Humans. Lung Neoplasms / drug therapy. Male. Melanoma / drug therapy. Prostatic Neoplasms / drug therapy. Sarcoma / drug therapy. Testicular Neoplasms / drug therapy. Thyroid Neoplasms / drug therapy. United States

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21220230.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


25. Tanigawa M, Kimura M, Ichioka M, Saito K, Kimura M: [A case of true pulmonary carcinosarcoma]. Nihon Kokyuki Gakkai Zasshi; 2003 Jul;41(7):496-501
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis was therefore true pulmonary carcinosarcoma.
  • The sarcoma component recurred in the remaining part of the left lung.
  • Nevertheless, chemotherapy, linac radiosurgery, percutaneous radiofrequency ablation, and partial small intestinal resection combined with rectal resection were performed.
  • At autopsy, a metastatic lesion was also detected in the pancreas.
  • Liver metastatic lesions were determined to be the adenocarcinomatous component, and the other recurrent or metastatic lesions, except for those in the brain, were all composed of poorly-differentiated sarcomatous tissue.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12931680.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


26. Newman S: Eribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer. Curr Opin Investig Drugs; 2007 Dec;8(12):1057-66
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer.
  • Eisai Co Ltd is developing eribulin, a simplified synthetic macrocyclic ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer.
  • Eribulin is currently in phase II trials for NSCLC and soft tissue sarcoma, and pancreatic, prostate, ovarian, fallopian tube, peritoneal and head and neck cancer, and phase I/II trials for urothelial cancers.
  • [MeSH-major] Antineoplastic Agents. Ethers, Cyclic / antagonists & inhibitors. Furans / therapeutic use. Ketones / chemistry. Neoplasms / drug therapy. Tubulin Modulators / antagonists & inhibitors
  • [MeSH-minor] Alopecia / chemically induced. Animals. Apoptosis / drug effects. Cell Line. Cell Line, Tumor. Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Clinical Trials, Phase III as Topic. Drug Evaluation, Preclinical. Fatigue / chemically induced. Humans. Hypoglycemia / chemically induced. Hypophosphatemia / chemically induced. Inhibitory Concentration 50. Macrolides. Molecular Structure. Multicenter Studies as Topic. Nausea / chemically induced. Neutropenia / chemically induced. Peripheral Nervous System Diseases / chemically induced. Randomized Controlled Trials as Topic. Survival Analysis. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18058576.001).
  • [ISSN] 1472-4472
  • [Journal-full-title] Current opinion in investigational drugs (London, England : 2000)
  • [ISO-abbreviation] Curr Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ethers, Cyclic; 0 / Furans; 0 / Ketones; 0 / Macrolides; 0 / Tubulin Modulators; 0 / eribulin; 103614-76-2 / halichondrin B
  •  go-up   go-down


27. Syed S, Takimoto C, Hidalgo M, Rizzo J, Kuhn JG, Hammond LA, Schwartz G, Tolcher A, Patnaik A, Eckhardt SG, Rowinsky EK: A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties. Clin Cancer Res; 2004 Oct 1;10(19):6512-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Major responses did not occur, but durable disease stability was noted in 3 patients, one each with carcinosarcoma of the uterus, pancreas, and ovary, all of whom had experienced disease progression before Col-3 treatment.
  • Pharmacokinetic results indicate that plasma concentrations above biologically relevant concentrations are readily maintained at this dose, and additional disease-directed studies, particularly in patients with soft tissue sarcoma, should be considered.
  • [MeSH-major] Antineoplastic Agents / pharmacokinetics. Matrix Metalloproteinase Inhibitors. Neoplasms / drug therapy. Tetracyclines / pharmacokinetics
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Anemia / chemically induced. Area Under Curve. Dose-Response Relationship, Drug. Fatigue / chemically induced. Female. Humans. Male. Matrix Metalloproteinases / metabolism. Metabolic Clearance Rate. Middle Aged. Nausea / chemically induced. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15475438.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA54174; United States / NCI NIH HHS / CA / CA69853; United States / NCRR NIH HHS / RR / M01 RR01346
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Matrix Metalloproteinase Inhibitors; 0 / Tetracyclines; 0 / tetracycline CMT-3; EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


28. Case CC, Vassilopoulou-Sellin R: Reproduction of features of the glucagonoma syndrome with continuous intravenous glucagon infusion as therapy for tumor-induced hypoglycemia. Endocr Pract; 2003 Jan-Feb;9(1):22-5
Hazardous Substances Data Bank. GLUCAGON .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reproduction of features of the glucagonoma syndrome with continuous intravenous glucagon infusion as therapy for tumor-induced hypoglycemia.
  • OBJECTIVE: To describe the adverse effects of continuous intravenous infusion of glucagon as therapy for tumor-induced hypoglycemia and to correlate these treatment-related effects with symptoms of endogenous hyper-glucagonemia.
  • METHODS: We reviewed three cases in which patients received continuous glucagon therapy for tumor-induced hypoglycemia and experienced adverse side effects to the treatment.
  • RESULTS: Continuous intravenous glucagon infusion has evolved as a reliable and efficacious modality for the treatment of tumor-induced hypoglycemia.
  • We report the adverse events of venous thromboembolism, necrolytic migratory erythema, and angular cheilitis in conjunction with continuous intravenous glucagon treatment.
  • These complications resemble symptoms that characterize the human model of hyperglucagonemia--the glucagonoma syndrome--which is associated with hyperglucagonemia and alpha-islet cell neoplasms of the pancreas.
  • [MeSH-major] Glucagon / therapeutic use. Glucagonoma / metabolism. Hypoglycemia / drug therapy. Hypoglycemia / etiology. Insulinoma / metabolism. Pancreatic Neoplasms / metabolism
  • [MeSH-minor] Drug Eruptions / pathology. Female. Hemangioma / complications. Humans. Infusions, Intravenous. Lung Neoplasms / complications. Male. Meningeal Neoplasms / complications. Middle Aged. Pleural Neoplasms / complications. Sarcoma / complications


29. O'Connell JB, Maggard MA, Ko CY: Cancer-directed surgery for localized disease: decreased use in the elderly. Ann Surg Oncol; 2004 Nov;11(11):962-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Previous studies report underuse of radiation and chemotherapy in the elderly, yet few have examined the rates of use (or underuse) of surgery.
  • METHODS: By using the Surveillance, Epidemiology, and End RESULTS database (1988-1997), patients (> or =40 years) were identified with localized adenocarcinoma of the breast, esophagus, stomach, pancreas, colon, or rectum; non-small-cell lung carcinoma; and sarcoma (n = 200,360).
  • Most striking were the low rates of CDS for patients >70 years with esophagus, stomach, pancreas, and lung cancers (range, 0%-83%).
  • For example, age significantly decreased the odds of receiving CDS beginning at 60 years for lung cancer (odds ratio [OR], .550; P = .03), at 70 years for liver cancer (OR, .109; P = .003), and at 80 years for pancreatic cancer (OR, .120; P < .05).

  • MedlinePlus Health Information. consumer health - Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2004 Nov;11(11):951-2 [15525821.001]
  • (PMID = 15525824.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. de Visser M, Janssen PJ, Srinivasan A, Reubi JC, Waser B, Erion JL, Schmidt MA, Krenning EP, de Jong M: Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer. Eur J Nucl Med Mol Imaging; 2003 Aug;30(8):1134-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer.
  • Neurotensin (NT) receptors are overexpressed in exocrine pancreatic cancer and Ewing's sarcoma.
  • The potential utility of native NT in cancer diagnosis and therapy is, however, limited by its rapid degradation in vivo.
  • All five NT analogues bound with high affinity to NT receptors on human exocrine pancreatic tumour sections.
  • The results of this study showed low percentages of injected dose per gram tissue of this (111)In-labelled 2530 analogue in receptor-negative organs like blood, spleen, pancreas, liver, muscle and femur.
  • With their enhanced stability, maintained high receptor affinity and rapid receptor-mediated internalisation, the (111)In-labelled DTPA- and DOTA-conjugated NT analogues are excellent candidates for imaging and therapy of exocrine pancreatic cancer, peptide 2530 being the most promising analogue.
  • [MeSH-major] Heterocyclic Compounds, 1-Ring / pharmacokinetics. Indium Radioisotopes / pharmacokinetics. Neurotensin / analogs & derivatives. Neurotensin / pharmacokinetics. Pancreatic Neoplasms / metabolism. Pentetic Acid / pharmacokinetics. Receptors, Neurotensin / metabolism
  • [MeSH-minor] Animals. Drug Evaluation, Preclinical. Drug Stability. Isotope Labeling / methods. Metabolic Clearance Rate. Mice. Mice, Nude. Organ Specificity. Pancreas / diagnostic imaging. Pancreas / metabolism. Pancreas / radiation effects. Radionuclide Imaging. Radiopharmaceuticals / chemical synthesis. Radiopharmaceuticals / pharmacokinetics. Radiopharmaceuticals / therapeutic use. Tissue Distribution. Whole-Body Counting

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1999 Jul 19;82(2):213-8 [10389755.001]
  • [Cites] J Nucl Med. 2001 Dec;42(12):1841-6 [11752083.001]
  • [Cites] J Nucl Med. 1999 Nov;40(11):1913-7 [10565789.001]
  • [Cites] Ann Surg. 2000 Jun;231(6):838-48 [10816627.001]
  • [Cites] Trends Pharmacol Sci. 1999 Jul;20(7):302-9 [10390649.001]
  • [Cites] Neuropharmacology. 1987 Jul;26(7B):911-6 [2821433.001]
  • [Cites] Semin Nucl Med. 2002 Apr;32(2):133-40 [11965608.001]
  • [Cites] Gut. 1999 Nov;45(5):766-74 [10517918.001]
  • [Cites] J Biol Chem. 2000 Jan 7;275(1):328-36 [10617622.001]
  • [Cites] J Nucl Med. 2002 Mar;43(3):374-83 [11884498.001]
  • [Cites] Life Sci. 1991;49(22):1593-601 [1658516.001]
  • [Cites] Int J Cancer. 1999 May 5;81(3):376-86 [10209952.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):437-41 [9458086.001]
  • [Cites] Nucl Med Commun. 1998 Mar;19(3):283-8 [9625504.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):5969-77 [2168286.001]
  • [Cites] Nucl Med Biol. 2002 Jan;29(1):61-72 [11786277.001]
  • [Cites] Int J Cancer. 2001 Jun 1;92(5):628-33 [11340564.001]
  • [Cites] Q J Nucl Med. 1999 Jun;43(2):155-8 [10429510.001]
  • [Cites] Nucl Med Biol. 2002 Apr;29(3):321-7 [11929702.001]
  • [Cites] Nucl Med Biol. 2001 Jan;28(1):75-84 [11182567.001]
  • [Cites] Life Sci. 1991;49(22):1583-91 [1658515.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):566-71 [10690540.001]
  • [Cites] Int J Cancer. 1999 Jan 29;80(3):448-54 [9935189.001]
  • [Cites] Gut. 1998 Apr;42(4):546-50 [9616318.001]
  • (PMID = 12768332.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Validation Studies
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Heterocyclic Compounds, 1-Ring; 0 / Indium Radioisotopes; 0 / Radiopharmaceuticals; 0 / Receptors, Neurotensin; 1HTE449DGZ / 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid; 39379-15-2 / Neurotensin; 7A314HQM0I / Pentetic Acid
  •  go-up   go-down


31. Grdina DJ, Murley JS, Kataoka Y, Baker KL, Kunnavakkam R, Coleman MC, Spitz DR: Amifostine induces antioxidant enzymatic activities in normal tissues and a transplantable tumor that can affect radiation response. Int J Radiat Oncol Biol Phys; 2009 Mar 1;73(3):886-96
Hazardous Substances Data Bank. AMIFOSTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amifostine induces antioxidant enzymatic activities in normal tissues and a transplantable tumor that can affect radiation response.
  • PURPOSE: To determine whether amifostine can induce elevated manganese superoxide dismutase (SOD2) in murine tissues and a transplantable SA-NH tumor, resulting in a delayed tumor cell radioprotective effect.
  • At selected time intervals after the last injection, the heart, liver, lung, pancreas, small intestine, spleen, and SA-NH tumor were removed and analyzed for SOD2, catalase, and glutathione peroxidase (GPx) enzymatic activity.
  • RESULTS: SOD2 activity was significantly elevated in selected tissues and a tumor 24 h after amifostine treatment.
  • GPx was also elevated in the pancreas.
  • If limited to normal tissues, this delayed radioprotective effect offers an additional potential for overall radiation protection.
  • However, amifostine-induced elevation of SOD2 activity in tumors could have an unanticipated deleterious effect on tumor responses to fractionated radiation therapy, given that the radioprotector is administered daily just before each 2-Gy fractionated dose.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Oct 1;18(19):3339-45 [11013273.001]
  • [Cites] Hum Gene Ther. 2008 Aug;19(8):820-6 [18699723.001]
  • [Cites] Drug Metabol Drug Interact. 2000;16(4):237-79 [11201306.001]
  • [Cites] Free Radic Biol Med. 2001 Jun 15;30(12):1426-39 [11390188.001]
  • [Cites] Int J Cancer. 2002 Jan 10;97(2):135-41 [11774255.001]
  • [Cites] Radiat Res. 2002 Jul;158(1):101-9 [12071809.001]
  • [Cites] Mol Cell Biol. 2003 Apr;23(7):2362-78 [12640121.001]
  • [Cites] Radiat Res. 2003 Nov;160(5):568-78 [14565825.001]
  • [Cites] Biochem Biophys Res Commun. 1976 Aug 23;71(4):952-8 [971321.001]
  • [Cites] Br J Radiol. 1978 Apr;51(604):291-301 [647186.001]
  • [Cites] Methods Enzymol. 1984;105:121-6 [6727660.001]
  • [Cites] Clin Exp Metastasis. 1985 Oct-Dec;3(4):281-94 [4075613.001]
  • [Cites] Cancer Res. 1988 Jul 1;48(13):3641-7 [2837320.001]
  • [Cites] Anal Biochem. 1989 May 15;179(1):8-18 [2547324.001]
  • [Cites] Nucleic Acids Res. 1992 Aug 11;20(15):3821-30 [1508666.001]
  • [Cites] Drug Metab Dispos. 1994 Nov-Dec;22(6):895-902 [7895607.001]
  • [Cites] Am J Physiol. 1995 Nov;269(5 Pt 1):L588-602 [7491977.001]
  • [Cites] Carcinogenesis. 1997 Nov;18(11):2113-7 [9395210.001]
  • [Cites] Free Radic Biol Med. 1998 Mar 1;24(4):586-93 [9559871.001]
  • [Cites] Semin Oncol. 1999 Apr;26(2 Suppl 7):34-6 [10348258.001]
  • [Cites] DNA Cell Biol. 1999 Sep;18(9):709-22 [10492402.001]
  • [Cites] Radiat Res. 2004 Nov;162(5):536-46 [15624308.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):784-91 [16198504.001]
  • [Cites] Free Radic Biol Med. 2006 Mar 15;40(6):1004-16 [16540396.001]
  • [Cites] Radiat Res. 2007 Apr;167(4):465-74 [17388698.001]
  • [Cites] In Vivo. 2007 Mar-Apr;21(2):141-6 [17436562.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):111-8 [17289291.001]
  • [Cites] Oncologist. 2007 Jun;12(6):738-47 [17602063.001]
  • [Cites] J Clin Oncol. 2007 Sep 10;25(26):4084-9 [17827457.001]
  • [Cites] Gene Ther. 2008 Mar;15(5):347-56 [18097469.001]
  • [Cites] Radiat Res. 2008 May;169(5):495-505 [18439041.001]
  • [Cites] Radiother Oncol. 2000 Nov;57(2):113-8 [11054513.001]
  • (PMID = 19215822.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA099005-04; United States / NCI NIH HHS / CA / P30 CA086862-069012; United States / NCI NIH HHS / CA / P30 CA086862; United States / NCI NIH HHS / CA / R01 CA099005; United States / NCI NIH HHS / CA / P01 CA086862; United States / NCI NIH HHS / CA / R01 CA99005; United States / NCI NIH HHS / CA / CA086862-069012; United States / NCI NIH HHS / CA / CA099005-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mercaptoethylamines; 0 / Radiation-Protective Agents; 31098-42-7 / WR 1065; EC 1.11.1.6 / Catalase; EC 1.11.1.9 / Glutathione Peroxidase; EC 1.15.1.1 / Superoxide Dismutase; EC 1.15.1.1 / superoxide dismutase 2; M487QF2F4V / Amifostine
  • [Other-IDs] NLM/ NIHMS96732; NLM/ PMC2668222
  •  go-up   go-down


32. Vail DM, Amantea MA, Colbern GT, Martin FJ, Hilger RA, Working PK: Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. Semin Oncol; 2004 Dec;31(6 Suppl 13):16-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Encapsulation of doxorubicin in polyethylene glycol-coated liposomes (Doxil/Caelyx [PLD]), was developed to enhance the safety and efficacy of conventional doxorubicin.
  • The liposomes alter pharmacologic and pharmacokinetic parameters of conventional doxorubicin so that drug delivery to the tumor is enhanced while toxicity normally associated with conventional doxorubicin is decreased.
  • In animals and humans, pharmacokinetic advantages of PLD include an increased area under the plasma concentration-time curve, longer distribution half-life, smaller volume of distribution, and reduced clearance.
  • In preclinical models, PLD produced remission and cure against many cancers including tumors of the breast, lung, ovaries, prostate, colon, bladder, and pancreas, as well as lymphoma, sarcoma, and myeloma.
  • It was also found to be effective as adjuvant therapy.
  • On the basis of pharmacokinetic and preclinical studies, PLD, either alone or as part of combination therapy, has potential applications to treat a variety of cancers.
  • [MeSH-minor] Animals. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Cetuximab. Drug Evaluation, Preclinical. Drug Resistance, Neoplasm. Drug Synergism. Humans. Liposomes / pharmacokinetics. Models, Animal. Trastuzumab

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15717736.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Liposomes; 80168379AG / Doxorubicin; P188ANX8CK / Trastuzumab; PQX0D8J21J / Cetuximab
  • [Number-of-references] 83
  •  go-up   go-down


33. Schöffski P, Breidenbach I, Krauter J, Bolte O, Stadler M, Ganser A, Wilhelm-Ogunbiyi K, Lentzen H: Weekly 24 h infusion of aviscumine (rViscumin): a phase I study in patients with solid tumours. Eur J Cancer; 2005 Jul;41(10):1431-8
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The MTD was defined as the dose level below the dose at which 2 patients per dose level experienced a DLT during the first treatment cycle.
  • Colorectal cancer, soft tissue sarcoma and pancreatic cancer were the most common tumour types.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Neoplasms / drug therapy. Plant Preparations / administration & dosage. Plant Proteins / administration & dosage. Toxins, Biological / administration & dosage
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. Middle Aged. Recombinant Proteins. Ribosome Inactivating Proteins, Type 2

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15913988.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Plant Preparations; 0 / Plant Proteins; 0 / Recombinant Proteins; 0 / Ribosome Inactivating Proteins, Type 2; 0 / Toxins, Biological; 0 / ribosome inactivating protein, Viscum
  •  go-up   go-down






Advertisement